Longboard Pharmaceuticals Announces Interim Results From 52-Week Open-Label Extension Of PACIFIC Study Evaluating Bexicaserin (LP352) In Participants With Developmental And Epileptic Encephalopathies
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals announced positive interim results from the 52-week open-label extension of the PACIFIC study evaluating Bexicaserin (LP352) in participants with developmental and epileptic encephalopathies. The study showed a median seizure reduction of 56.1% over approximately 6 months, with favorable safety and tolerability results. An End of Phase 2 Meeting is scheduled for this summer.
June 10, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longboard Pharmaceuticals announced positive interim results from the PACIFIC study on Bexicaserin (LP352), showing a 56.1% median seizure reduction and favorable safety and tolerability. An End of Phase 2 Meeting is scheduled for this summer.
The positive interim results from the PACIFIC study indicate significant progress in the development of Bexicaserin (LP352), which could lead to increased investor confidence and a potential rise in LBPH's stock price. The upcoming End of Phase 2 Meeting adds further anticipation for future developments.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100